Holen Sie sich die Stockscreener-App
3.91
37.04%
-2.30
Handel nachbörslich:
3.97
0.06
+1.53%
Schlusskurs vom Vortag:
$6.21
Offen:
$4.035
24-Stunden-Volumen:
42.98M
Relative Volume:
12.90
Marktkapitalisierung:
$477.03M
Einnahmen:
$58.36M
Nettoeinkommen (Verlust:
$-25.72M
KGV:
-10.74
EPS:
-0.3641
Netto-Cashflow:
$-24.91M
1W Leistung:
-39.38%
1M Leistung:
-35.90%
6M Leistung:
-2.49%
1J Leistung:
+24.92%
1-Tages-Spanne:
$3.585
$4.15
1-Wochen-Bereich:
$3.585
$6.47
52-Wochen-Spanne:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Firmenname
Aquestive Therapeutics Inc
Sektor
Telefon
908-941-1900
Adresse
30 TECHNOLOGY DRIVE, WARREN, NJ
Vergleichen Sie AQST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.91 | 757.64M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | Raymond James | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-04-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-03 | Eingeleitet | Lake Street | Buy |
| 2018-08-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-08-20 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten
AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed - Stocktwits
Aquestive Therapeutics Inc. (AQST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Sector Update: Health Care - MarketScreener
Aquestive Therapeutics Stock Dips Amid Financial Challenges - StocksToTrade
INVESTOR ALERT: Investigation of Aquestive Therapeutics, Inc. (AQST) by Holzer & Holzer, LLC - GlobeNewswire
Is Aquestive Therapeutics Inc. stock oversold or undervalued2025 Price Targets & Accurate Entry and Exit Point Alerts - ulpravda.ru
Oklo, Applied Digital, Opendoor Technologies, Vistra, Aquestive Therapeutics: Stocks making the biggest moves today - MSN
Oklo, Applied Digital, Opendoor Technologies, Vistra, Aquestive Therapeutics: Stocks Making The Biggest Moves Today - Asianet Newsable
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - 巴士的報
FDA Identifies NDA Deficiencies for Anaphylm as Review Continues, Aquestive Therapeutics Announces - Patient Care Online
BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies ... - Bluefield Daily Telegraph
BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies Deficiencies; Investors Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewswire
Aquestive Therapeutics Faces Turbulent Market While Strategizing for Future Growth - timothysykes.com
FDA setback for Aquestive Thera’s Anaphylm - The Pharma Letter
Aquestive Therapeutics Stock (AQST) Opinions on FDA Deficiency Notice - Quiver Quantitative
Aquestive announces FDA identified deficiencies in NDA for Anaphylm - TipRanks
Why Is Aquestive Therapeutics Stock (AQST) Down Today? - TipRanks
Aquestive stock falls after FDA cites deficiencies in Anaphylm application By Investing.com - Investing.com South Africa
Aquestive stock falls after FDA cites deficiencies in Anaphylm application - Investing.com
Aquestive Faces FDA Deficiencies on Anaphylm NDA Review - TipRanks
Aquestive says FDA cited issues with Anaphylm (AQST:NASDAQ) - Seeking Alpha
Aquestive Therapeutics falls as FDA flags issues with oral allergy drug - TradingView — Track All Markets
Aquestive Therapeutics, Inc. Reports FDA Notice on Anaphylm NDA - TradingView — Track All Markets
FDA identifies deficiencies in Aquestive’s Anaphylm application By Investing.com - Investing.com India
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Aquestive Therapeutics Announces Regulatory Development for - GlobeNewswire
Aquestive Therapeutics: Looking For The PDUFA Run-Up (NASDAQ:AQST) - Seeking Alpha
How risky is Aquestive Therapeutics Inc. stock nowJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Market Trends: How Aquestive Therapeutics Inc. stock benefits from tech adoptionDip Buying & Stepwise Entry and Exit Trade Signals - ulpravda.ru
Los Angeles Daily NewsAquestive Therapeutics, Inc.Common Stock (Nasdaq:AQST) Stock Quote - FinancialContent
Published on: 2026-01-09 02:35:53 - ulpravda.ru
What catalysts could drive Aquestive Therapeutics Inc. stock higherSwing Trade & Risk Managed Investment Signals - ulpravda.ru
How Aquestive Therapeutics Inc. stock benefits from tech adoptionMarket Movement Recap & Real-Time Stock Entry Alerts - ulpravda.ru
Is Aquestive Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 WrapUp & Real-Time Market Trend Scan - ulpravda.ru
Aquestive Therapeutics, Inc.Common Stock (NQ: AQST - FinancialContent
Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why - sharewise.com
Why Aquestive Therapeutics Inc. stock could see breakout soonTrade Execution Strategies & Exceptional Profit Ideas - ulpravda.ru
Breakeven On The Horizon For Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Yahoo Finance
Aquestive completes marketing application for Anaphylm in U.S. - MSN
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 5.7%Should You Buy? - MarketBeat
Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care - HCPLive
Aquestive Therapeutics, Inc.(NasdaqGM:AQST) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Aquestive Therapeutics (NASDAQ:AQST) shareholders are still up 524% over 3 years despite pulling back 6.6% in the past week - simplywall.st
Is Aquestive Therapeutics Inc. stock gaining market shareWeekly Earnings Recap & Growth Focused Entry Point Reports - Улправда
Is Aquestive Therapeutics Inc. stock a buy on dips2025 Valuation Update & Entry Point Confirmation Signals - Улправда
How rising interest rates impact Aquestive Therapeutics Inc. stock2025 Retail Activity & Long-Term Growth Portfolio Plans - Улправда
Published on: 2025-12-19 18:44:27 - DonanımHaber
What dividend safety score for Aquestive Therapeutics Inc. stockJuly 2025 News Drivers & Scalable Portfolio Growth Methods - DonanımHaber
Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):